Evidence map›Paper›PMID 40415475›Full record

ReviewNanomedicine (London, England)2025

A drug delivery perspective on nanotechnology-based topical therapeutics for inflammatory skin diseases.

Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Allana Carolina Leme de Almeida, Felipe Mota Tashiro, Isabel Rheinfranck Peleje, Marlus Chorilli

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Polymeric Nanogels for Skin Applications.Gels (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leonardo Delello Di FilippoDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University "Júlio de Mesquita Filho", Araraquara, Brazil.
Jonatas Lobato DuarteDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University "Júlio de Mesquita Filho", Araraquara, Brazil.
Allana Carolina Leme de AlmeidaDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University "Júlio de Mesquita Filho", Araraquara, Brazil.
Felipe Mota TashiroDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University "Júlio de Mesquita Filho", Araraquara, Brazil.
Isabel Rheinfranck PelejeDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University "Júlio de Mesquita Filho", Araraquara, Brazil.
Marlus ChorilliDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University "Júlio de Mesquita Filho", Araraquara, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory skin diseases are chronic conditions that significantly affect patients' skin health and quality of life. Traditional treatments, including systemic immunosuppressants and topical therapies, often face limitations such as low efficacy, inadequate skin penetration, and severe side effects. Nanotechnology has emerged as a promising solution to tackle these challenges by providing innovative drug delivery systems that not only enhance therapeutic precision but also reduce systemic exposure. This review highlights the technological innovations and pre-clinical potential of nanotechnology-based therapies in managing inflammatory skin diseases, emphasizing their advantages over conventional treatments and their ability to overcome existing therapeutic limitations. Drug delivery nanosystems like lipid, polymeric, and metallic nanocarriers can be designed to penetrate the skin barrier and deliver drugs directly to the affected tissues. These nanocarriers improve drug stability, bioavailability, and retention in target areas while minimizing adverse effects. Furthermore, nanoparticles can be functionalized with bioadhesive molecules (e.g. hyaluronic acid) to achieve targeted and sustained drug release. In preclinical studies, such advanced formulations have demonstrated the potential to modulate immune responses and reduce inflammation by delivering therapeutics in a controlled and localized manner.

Indexed as

Drug Delivery SystemsNanoparticlesSkin DiseasesAdministration, CutaneousAdministration, TopicalAnimalsDrug CarriersHumansInflammationNanotechnologySkinDrug Carriersdrug deliveryInflammationnanotechnologyskin barrierskin diseases

Identifiers

PMID40415475
PMCPMC12143682

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.